510(k) Report

510(k) · Cleared

Cleared

CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System; CONTOUR® NEXT ONE Blood Glucose Monitoring System

K260545510(k) TraditionalCleared Aug 27, 2026190-day reviewClass II21 CFR 862.1345

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Ascensia Diabetes Care · NBW System, Test, Blood Glucose, Over The Counter

Cleared on Aug 27, 2026 as substantially equivalent to K241787 (Ascensia Diabetes Care U.S., Inc., 2024) after a 190-day review. Its family tree reaches back 10 generations to 2003.

Decided
Aug 27, 2026
Review
190 days
Class
Class II
Product code
NBW
Recalls
None
Predicates
1

Its longest line of descent runs back 10 generations to K030531 (2003). 13 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 10 generations backK030531 Medtronic Minimed Paradigm Model 512 Insulin Pump and the BD…Minimed, Inc. · 2003 · Recalled
  2. 6 generations between
  3. 3 generations backK193407 Contour® next GEN Blood Glucose Monitoring SystemAscensia Diabetes Care · 2021 · Recalled
  4. 2 generations backK223293 CONTOUR® NEXT GEN Blood Glucose Monitoring SystemAscensia Diabetes Care U.S., Inc. · 2022
  5. 1 generation backK241787 CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT…Ascensia Diabetes Care U.S., Inc. · 2024
  6. This deviceK260545 CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT…Ascensia Diabetes Care · 2026
Show all 10 generations
  1. Root · 10 generations backK030531 Medtronic Minimed Paradigm Model 512 Insulin Pump and the BD…Minimed, Inc. · 2003 · Recalled
  2. 9 generations backK040603 Paradigm Link Blood Glucose MeterBecton, Dickinson & CO · 2004
  3. 8 generations backK073231 Onetouch Ultralink Blood Glucose Monitoring SystemLifescan, Inc. · 2008
  4. 7 generations backK110894 Contour Next Link Wireless Blood Glucose MeterBayer Healthcare · 2012
  5. 6 generations backK121087 Contour Next Usb Blood Glucose Monitoring SystemBayer Healthcare · 2012
  6. 5 generations backK150942 Contour Next USB Blood Glucose Monitoring SystemBayer Healthcare · 2015
  7. 4 generations backK160682 CONTOUR NEXT ONE Blood Glucose Monitoring SystemAscensia Diabetes Care · 2016
  8. 3 generations backK193407 Contour® next GEN Blood Glucose Monitoring SystemAscensia Diabetes Care · 2021 · Recalled
  9. 2 generations backK223293 CONTOUR® NEXT GEN Blood Glucose Monitoring SystemAscensia Diabetes Care U.S., Inc. · 2022
  10. 1 generation backK241787 CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT…Ascensia Diabetes Care U.S., Inc. · 2024
  11. This deviceK260545 CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT…Ascensia Diabetes Care · 2026
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−10K030531Medtronic Minimed Paradigm Model 512 Insulin Pump and the BD Paradigm Link…Minimed, Inc.20033
−9K040603Paradigm Link Blood Glucose MeterBecton, Dickinson & CO2004—
−8K073231Onetouch Ultralink Blood Glucose Monitoring SystemLifescan, Inc.2008—
−7K110894Contour Next Link Wireless Blood Glucose MeterBayer Healthcare2012—
−6K121087Contour Next Usb Blood Glucose Monitoring SystemBayer Healthcare2012—
−5K150942Contour Next USB Blood Glucose Monitoring SystemBayer Healthcare2015—
−4K160682CONTOUR NEXT ONE Blood Glucose Monitoring SystemAscensia Diabetes Care2016—
−3K193407Contour® next GEN Blood Glucose Monitoring SystemAscensia Diabetes Care20211
−2K223293CONTOUR® NEXT GEN Blood Glucose Monitoring SystemAscensia Diabetes Care U.S., Inc.2022—
−1K241787CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood…Ascensia Diabetes Care U.S., Inc.2024—
0 (this device)K260545CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood…Ascensia Diabetes Care2026—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200610
200710
200910
FIG. 1 — Lineage of K260545, 2003–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NBW? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NBW device

  1. #1 K241787 CONTOUR® PLUS BLUE Blood Glucose Monitoring…score 13.3 · 9 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K241787CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose…
Summary page 7
…21 CFR 807.92(a)(3) Predicate # Predicate Trade Name (Primary Predicate is listed first) Product Code K241787 CONTOUR® PLUS BLUE Blood Glucose Monitoring System NBW Device De…
Ascensia Diabetes Care U.S., Inc.2024—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 23 years and passes through 6 companies; a new generation was cleared every 2.0 years on median.
  • 2 of the 13 ancestors have a recall of any class.

How does its category compare?

All NBW devices

NBW System, Test, Blood Glucose, Over The Counter: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.

FDA decisions per year · NBW

2in 2025

2007: 292008: 372009: 382010: 312011: 302012: 302013: 472014: 242015: 322016: 202017: 252018: 192019: 102020: 72021: 72022: 122023: 52024: 72025: 22026 (partial year): 5
2007high 47 (2013) · low 2 (2025)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NBW

243in 2024

2007: 85 days median2008: 128 days median2009: 140 days median2010: 132 days median2011: 328 days median2012: 230 days median2013: 167 days median2014: 202 days median2015: 237 days median2016: 233 days median2017: 244 days median2018: 168 days median2019: 127 days median2020: 121 days median2021: 465 days median2022: 410 days median2023: 193 days median2024: 243 days median2026 (partial year): 190 days median
2007high 465 (2021) · low 85 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NBW

1in 2025

2007: 92008: 22009: 52010: 112011: 12012: 12013: 5, 2 Class I2014: 12016: 12019: 142025: 1
2007high 14 (2019) · low 0 (2015)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · NBW

4,745in 2025

2007: 7,9912008: 7,7042009: 10,9632010: 11,6312011: 22,9092012: 23,4492013: 35,4082014: 38,5242015: 62,1112016: 76,6212017: 37,5382018: 16,9112019: 14,4722020: 10,7032021: 9,1982022: 8,1032023: 7,2562024: 6,2202025: 4,745
2007high 76,621 (2016) · low 4,745 (2025)2025

MAUDE reports naming product code NBW, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007298597,991
20083712827,704
200938140510,963
2010311321111,631
201130328122,909
201230230123,449
2013471675 (2)35,408
201424202138,524
201532237062,111
201620233176,621
201725244037,538
201819168016,911
2019101271414,472
20207121010,703
2021746509,198
20221241008,103
2023519307,256
2024724306,220
20252—14,745
202651900—

What is it indicated for?

The CONTOUR® PLUS BLUE blood glucose monitoring system consists of the CONTOUR® PLUS BLUE meter, the CONTOUR® PLUS blood glucose test strips, and the CONTOUR™DIABETES App. The CONTOUR® PLUS BLUE blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips. The CONTOUR® PLUS BLUE blood glucose monitoring system is intended to be used by a single person and…

Read the full statement (518 words)

The CONTOUR® PLUS BLUE blood glucose monitoring system consists of the CONTOUR® PLUS BLUE meter, the CONTOUR® PLUS blood glucose test strips, and the CONTOUR™DIABETES App.

The CONTOUR® PLUS BLUE blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips. The CONTOUR® PLUS BLUE blood glucose monitoring system is intended to be used by a single person and should not be shared. The CONTOUR® PLUS BLUE blood glucose monitoring system is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program.

The CONTOUR® PLUS BLUE blood glucose monitoring system should not be used for the diagnosis of or screening for diabetes or for neonatal use. The CONTOUR® PLUS blood glucose test strips are for use with the CONTOUR® PLUS BLUE meter to quantitatively measure glucose in fresh capillary whole blood drawn from the fingertips.

The system is intended for in vitro diagnostic use only.

The CONTOUR® NEXT GEN Blood Glucose Monitoring System consists of the CONTOUR® NEXT GEN meter, CONTOUR® NEXT blood glucose test strips and the CONTOUR™DIABETES App.

The CONTOUR® NEXT GEN Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips. The CONTOUR® NEXT GEN Blood Glucose Monitoring System is intended to be used by a single person and should not be shared. The CONTOUR® NEXT GEN Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program.

The CONTOUR® NEXT GEN Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes or for neonatal use.

The system is intended for in vitro diagnostic use only.

The CONTOUR® NEXT ONE Blood Glucose Monitoring System consists of the CONTOUR® NEXT ONE meter, CONTOUR® NEXT blood glucose test strips and the CONTOUR™DIABETES App.

The CONTOUR® NEXT ONE Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips or palm. The CONTOUR® NEXT ONE Blood Glucose Monitoring System is intended to be used by a single person and should not be shared. The CONTOUR® NEXT ONE Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program.

The CONTOUR®NEXT ONE Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes or for neonatal use. Alternative site testing (palm) should be done only during steady state times (when glucose is not changing rapidly). The CONTOUR® NEXT test strips are for use with the CONTOUR® NEXT ONE blood glucose meter to quantitatively measure glucose in fresh capillary whole blood drawn from the fingertips or palm.

The system is intended for in vitro diagnostic use only.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K260545: CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System; CONTOUR® NEXT ONE Blood Glucose Monitoring System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K260545

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded Oct 30, 2026
  • Summary read Oct 30, 2026 (extraction version 2d9447fa9ea4)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026